SEARCH

SEARCH BY CITATION

Bibliography

  • 1
    D'Amico G & Luca A. Natural History: clinical-haemodynamic correlations: prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997; 11: 24356.
  • 2
    Williams SG & Westaby D. Management of variceal haemorrhage. BMJ 1994; 308(6938): 12137.
  • 3
    Calès P, Oberti F & Payen JL, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomised trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol 1999; 11(7): 7415.
  • 4
    Boyer TD, Triger DR, Horisawa M, Redeker AG & ReyoLds TB. Direct measurement of portal vein pressure using a thin needle. Gastroenterology 1977; 72: 5849.
  • 5
    Lin H, Tsai Y & Lee F, et al. Comparison between portal vein pressure and wedge hepatic vein pressure in hepatitis B-related cirrhosis. J Hepatol 1989; 9: 32630.
  • 6
    Perello A, Escorsell A & Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999; 30(6): 13937.
  • 7
    Groszmann RJ, Bosch J & Grace ND, et al. Hemodynamic events in a prospective randomised trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99(5): 14017.
  • 8
    Feu F, Garcia-Pagan JC & Bosch J, et al. Relationship between portal pressure response to pharmacotherapy and risk of recurrent variceal heamorrhage in patients with cirrhosis. Lancet 1995; 346: 10569.
  • 9
    Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O & Benhamou JP. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982; 2(5): 5237.
  • 10
    Zoli M, Marchesini G, Brunori A, Cordiani MR & Pisi E. Portal venous flow in response to acute β-blocker and vasodilatatory treatment in patients with liver cirrhosis. Hepatology 1986; 6(6): 124851.
  • 11
    Bosch J, Masti R & Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4(6): 12005.
  • 12
    Mastai R, Bosch J & Navasa M, et al. Effects of alpha-adrenergic stimulation and β-adrenergic blockage on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1987; 4(1): 719.
  • 13
    Vorobioff J, Picabea E & Villavicencio R, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7(4): 64853.
  • 14
    Westaby D, Bihari DJ, Gimson AE, Crossley IR & Williams R. Selective and non-selective β-blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut 1984; 25: 1214.
  • 15
    Braillon A, Lee SS, Valla D, Geoffroy P, Sauvanet JP & Lebrec D. Comparative haemodynamic effects of β-xolol and propranolol in patients with cirrhosis. Scand J Gastroenterol 1988; 23(6): 6915.
  • 16
    Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P & Rodes J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990; 11(2): 2308.
  • 17
    Garcia-Pagan JC, Feu F, Bosch J & Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomised controlled study. Ann Intern Med 1991; 114(10): 86973.
  • 18
    Bendtsen F, Henriksen JH & Sorensen TT. Long-term effects of oral propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis and oesophageal varices. Scand J Gastroenterol 1991; 26(9): 9339.
  • 19
    Aramaki T, Sekiyama T & Katsuta Y, et al. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new β-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol. J Hepatol 1992; 15(1–2): 4853.
  • 20
    Vorobioff J, Picabea E & Gamen M, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepatology 1993; 18(3): 47784.
  • 21
    Braillon A, Cales P, Valla D, Gaudy D, Geoffroy P & Lebrec D. Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986; 27(10): 12049.
  • 22
    Kroeger RJ & Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of β-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985; 5(1): 97101.
  • 23
    Walle T, Webb JG & Bagwell EE, et al. Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol 1988; 37(1): 11524.
  • 24
    Schepke M, Raab P & Hoppe A, et al. Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. Aliment Pharmacol Ther 1999; 3(11): 14518.
  • 25
    Feu F, Bordas JM & Luca A, et al. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology 1993; 18(5): 10829.
  • 26
    McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N & Burroughs AK. Clinical vs. haemodynamic response to drugs in portal hypertension. J Hepatol 1998; 28(6): 10159.
  • 27
    Stanley AJ, Robinson I, Forrest EH, Jones AL & Hayes PC. Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. QJM 1998; 91(1): 1925.DOI: 10.1093/qjmed/91.1.19
  • 28
    Jalan R, Redhead DN, Forrest EH & Hayes PC. Relationship between directly measured portal pressure gradient and variceal heamorrhage. Am J Gastroenterol 1995; 90(11): 199496.
  • 29
    Gatta A, Sacerdoti D, Merkel C, Milani L, Battaglia G & Zuin R. Effects of Nadalol treatment on renal and hepatic haemodynamics and function in cirrhotic patients with portal hypertension. Am Heart J 1984; 108(4 Pt 2): 116772.
  • 30
    Gatta A, Sacerdoti D & Merkel C, et al. Use of a non-selective β-blocker, nadolol, in the treatment of portal hypertension in cirrhotics. Int J Clin Pharmacol Res 1985; 5(6): 4138.
  • 31
    Gatta A, Bolognesi M & Merkel C, et al. Long-term effects of β-adrenergic blockade with nadolol on hepatic and renal haemodynamics and function in cirrhotics. Clin Physiol 1987; 7(5): 37787.
  • 32
    Merkel C, Sacerdoti D & Finucci GF, et al. Effect of nadolol on liver haemodynamics and function in patients with cirrhosis. Br J Clin Pharmacol 1986; 21(6): 7139.
  • 33
    Bolognesi M, Sacredoti D, Merkel C & Gatta A. Duplex-doppler sonographic evaluation of splancnic and renal effects of single-agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic-patients. J Ultrasound Med 1994; 13(12): 945952.
  • 34
    Escorsell A, Ferayorni L & Bosch J, et al. The portal pressure response to β-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997; 112(6): 20126.
  • 35
    Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G & Benhamou JP. Comparison of the effects of a cardioselective and noncardioselective β-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982; 2(5): 52831.
  • 36
    Mills PR, Rae AP, Farah DA, Russell RI, Lorimer AR & Carter DC. Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut 1984; 25(1): 738
  • 37
    Westaby D, Bihari DJ, Gimson AE, Crossley JR & Williams R. Selective and non-selective β-receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal patients. Gut 1984; 25(2): 1214.
  • 38
    Bihari D, Westaby D, Gimson A, Crossley I, Harry J & Williams R. Reductions in portal pressure by selective β-2-adrenoceptor blockade in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol 1984; 17(6): 7537.
  • 39
    Braillon A, Cales P & Lebrec D. Comparison of the short-term effects of mepindolol and propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis. Int J Clin Pharmacol Res 1985; 5(4): 2238.
  • 40
    Forrest EH, Bouchier IA & Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating β-blocker, in patients with cirrhosis. J Hepatol 1996; 25(6): 90915.
  • 41
    Stanley AJ, Therapondos G, Helmy A & Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999; 30(3): 47984.
  • 42
    Banares R, Moitinho E & Piqueras B, et al. Carvedilol, a new nonselective β-blocker with intrinsic anti-alpha1 adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999; 30(1): 7983.
  • 43
    Lui HF, Therapondos G, Stanley AJ & Hayes PC. Acute and chronic haemodynamic effects of low dose carvedilol in patients with cirrhosis. Hepatology 1999; 30(4): 572A572A.
  • 44
    Abshagen U, Betzien G, Endele R, Kaufmann B & Neugebauer G. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Eur J Clin Pharmacol 1985; 27(6): 63744.
  • 45
    Straehl P & Galeazzi RL. Isosorbide dinitrate bioavailability, kinetics, and metabolism. Clin Pharmacol Ther 1985; 38(2): 1409.
  • 46
    Abshagen UW. Pharmacokinetics of isosorbide mononitrate. Am J Cardiol 1992; 70(17): 61G6G.
  • 47
    Jones AL & Hayes PC. Organic nitrates in portal hypertension. Am J Gastroenterol 1994; 89(1): 714.
  • 48
    Hayes PC, Westaby D & Williams R. Effect and mechanism of action of isosorbide-5-mononitrate. Gut 1988; 29: 7525.
  • 49
    Tsai YT, Lee FY & Lin HC, et al. Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis. Hepatology 1989; 10(3): 2837.
  • 50
    Navasa M, Chesta J, Bosch J & Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989; 96(4): 11108.
  • 51
    Garcia-Pagan JC, Feu F & Navasa M, et al. Long-term haemodynamic effects of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990; 11(2): 18995.
  • 52
    Grose RD, Plevris JN, Redhead DN, Bouchier IA & Hayes PC. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis. J Hepatol 1994; 20(4): 5427.
  • 53
    Jones AL, Bangash IH, Walker J, Simpson KJ, Finlayson ND & Hayes PC. Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis. Gut 1995; 36(1): 1049.
  • 54
    Escorsell A, Feu F & Bordas JM, et al. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1996; 24(4): 4239.
  • 55
    Forrest EH, Jalan R, Redhead DN & Hayes PC. Differing actions of the acute administration of propranolol and isosorbide-5-mononitrate on the portal circulation. Aliment Pharmacol Ther 1996; 10(5): 795800.
  • 56
    Lautt WW. Mechanism and role or intrinsic regulation of hepatic arterial blood flow: the hepatic arterial buffer response. Am J Physiol 1985; 240: G54956.
  • 57
    Bosch J & Groszmann RJ. Measurement of azygous venous blood flow as an index of variceal blood flow in cirrhosis and portal hypertension. Hepatology 1982; 5: 707707.
  • 58
    Elkayam U, Kulick D & Mcintosh N. Incidence of early tolerance to heamodynamic effects of continuos infusions of nitroglycerin in patients with coronary heart disease and heart failure. Circulation 1987; 76: 57784.
  • 59
    Jugdutt BI & Warnica W. Tolerance with low dose intravenous nitroglycerin therapy in acute myocardial therapy. Am J Cardiology 1989; 64: 5817.
  • 60
    Salmeron JM, Ruiz del Arbol L & Gines A, et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 1993; 17(5): 8006.
  • 61
    Albillos A, Lledo JL & Banares R, et al. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994; 20(3): 6117.
  • 62
    Albillos A, Lledo JL & Rossi I, et al. Continuous prazosin in administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995; 109(4): 125765.
  • 63
    Willett IR, Esler M, Jennings G & Dudley FJ. Sympathetic tone modulates portal venous pressure in alcoholic cirrhosis. Lancet 1986; 2(8513): 93943.
  • 64
    Moreau R, Lee SS, Hadengue A, Braillon A & Lebrec D. Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology 1987; 7(1): 14954.
  • 65
    Esler M, Dudley F & Jennings G, et al. Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis. Ann Intern Med 1992; 116(6): 44655.
  • 66
    Albioss A, Banares R & Barrios C, et al. Long-term administration of clonidine in patients with alcoholic cirrhosis. Haemodynamic and liver function effects. Gastroenterology 1992; 102: 24854.
  • 67
    Tincani E, Cioni G & D'Alimonte P, et al. Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography. Eur J Gastroenterol Hepatol 1995; 7(9): 8937.
  • 68
    Garcia-Pagan JC, Bosch J & Rhodes J. The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis 1995; 6: 1407.
  • 69
    Ballet F, Chretien Y, Rey C & Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther 1988; 244: 2335.
  • 70
    Schneider AW, Kalk JF & Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 3349.
  • 71
    Debernardi-Venon W, Barletti C & Marzano A, et al. Efficacy of Irbesartan, an angiotensin II receptor selective antagonist, in the treatment of portal hypertension. [Abstract] Hepatology 1999; 30(4): 219A219A.
  • 72
    Gentilini P, Romanelli RG & La Villa G, et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993; 104(2): 58894.
  • 73
    Cummings SA, Groszmann RJ & Kaumann AJ. Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 1986; 89(3): 50113.
  • 74
    Hadengue A, Lee SS, Moreau R, Braillon A & Lebrec D. Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanisms in portal hypertension. Hepatology 1987; 7(4): 6447.
  • 75
    Deflandre J, Pirotte J, Etienne M & Carlier J. Effect of a serotonin S2 receptor antagonist on portal hypertension due to cirrhosis. Preliminary results of a heart and liver hemodynamic study. Ann Gastroenterol Hepatol (Paris) 1988; 24(3): 1035.
  • 76
    Vorobioff J, Garcia-Tsao G & Groszmann R, et al. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 1989; 9(1): 8891.
  • 77
    Hadengue A, Moreau R, Cerini R, Koshy A, Lee SS & Lebrec D. Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. Hepatology 1989; 9(1): 837.
  • 78
    Ladero Quesada JM, Diez Ordonez S, Gallego Beuter JJ, Hernandez Lezana A, Herraiz Serrano ML & Diaz-Rubio Garcia M. Addition of ritanserin to the treatment with propranolol in cirrhotic patients: effects on portal pressure. An Med Interna 1994; 11(4): 1626.
  • 79
    Zimmon DS & Kessler RE. The portal pressure-blood volume relationship in cirrhosis. Gut 1974; 15: 99101.
  • 80
    Klein CP. Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle? Dtsch Med Wochenschr 1985; 110(46): 17746.
  • 81
    Katsuta Y, Aramaki T, Sekiyama T, Satomura K & Okumura H. Plasma volume contraction in portal hypertension. J Hepatol 1993; 17(Suppl. 2): S1923.
  • 82
    Garcia-Pagan JC, Salmeron JM & Feu F, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994; 19(5): 10959.
  • 83
    Sugano S, Kawafune T, Okajima T, Ishii K, Watanabe M & Takamura N. Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci 1998; 43(4): 8937.
  • 84
    Nevens F, Lijnen P, VanBilloen H & Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996; 23(5): 104752.
  • 85
    Abecais R, Kravetz D & Fassio E, et al. Nadolol plus spironolactone vs. nadolol alone in the prophylaxis of the first variceal bleeding in non-ascitic cirrhotic patients. Preliminary results of a multicenter, double blind and randomised trial [Abstract]. Hepatology 1997; 26(Suppl.): 135A135A.
  • 86
    Groszmann RJ, Kravetza D & Bosch J, et al. Nitrogylcerin improves the haemodynamic response to vasopressin in portal hypertension. Hepatology 1982; 2(6): 75762.
  • 87
    Hallemans R, Naeije R, Mols P, Melot C & Reding P. Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin. Crit Care Med 1983; 11(7): 53640.
  • 88
    Kroeger RJ & Groszmann RJ. The effect of the combination of nitroglycerin and propranolol on splancnic and systemic haemodynamics in a portal hypotensive rat model. Hepatology 1985; 5: 42530.
  • 89
    Morillas RM, Planas R & Cabre E, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology 1994; 20(6): 15028.
  • 90
    Merkel C, Gatta A & Donada C, et al. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l’Ipertensione Portale. Hepatology 1995; 22(3): 80813.
  • 91
    Merkel C, Sacerdoti D & Bolognesi M, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the β-blocker alone. Hepatology 1997; 26(1): 349.
  • 92
    Albillos A, Garcia-Pagan JC & Iborra J, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998; 115(1): 11623.
  • 93
    Merkel C, Sacerdoti D & Bolognesi M, et al. Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis. Eur J Gastroenterol Hepatol 1999; 11(11): 12215.
  • 94
    Pascal JP & Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987; 317(14): 85661.
  • 95
    The Italian Multicentre Project for Propranolol in Preventon of Bleeding. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomised trial. J Hepatol 1989; 9: 7583.
  • 96
    Conn HO, Grace ND & Bosch J, et al. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomised clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. Hepatology 1991; 13(5): 90212.
  • 97
    Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomised multicenter trial. The PROVA Study Group. Hepatology 1991; 14: 101624.
  • 98
    Andreani T, Poupon RE & Balkau B, et al. Preventative therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology 1990; 12: 141319.
  • 99
    Strauss E, De Sa MFG, Albano A, Lacet CMC, Leite MO & Maffei RA. A randomised controlled trial for the prevention of the first upper gastrointestinal bleeding due to portal hypertension in cirrhosis: sclerotherapy or propranolol versus control groups [Abstract]. Hepatology 1988; 8: 13951395.
  • 100
    Colman J, Jones P, Finch C & Dudley F. Propranolol in prevention of variceal haemorrhage in alcoholic cirrhotic patients [Abstract]. Hepatology 1990; 12: 851851.
  • 101
    Ideo G, Bellati G, Fesce E & Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective randomised study. Hepatology 1988; 8: 69.
  • 102
    Lebrec D, Poynard T & Capron JP, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomise study. J Hepatol 1988; 7: 118125.
  • 103
    Plevris JN, Eliot R & Mills PR, et al. Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease. Aliment Pharmacol Ther 1994; 8: 6370.
  • 104
    Hayes PC, Davis JM, Lewis JA & Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990; 336: 1536.
  • 105
    Poynard T, Cales P & Pasta L, et al. β-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomised clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991; 324(22): 15328.
  • 106
    D'Amico G, Pagliaro L & Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22(1): 33254.
  • 107
    Fassio E, Viudez P, Fernandez N, Landeira G & Longo C. Isosorbide-5-mononitrate in the prevention of digestive heamorrhage in cirrhosis: randomised study. Acta Gastroenterol Latinoam 1993; 23(4): 21722.
  • 108
    García-Pagan JC for the Spanish Variceal Bleeding Study Group. Isosorbide-5-mononitrate (ISMN) vs. placebo (PLA) in prevention of the first variceal bleeding (FVB) in patients with contraindications or intolerance of β-blockers [Abstract]. J Hepatol 2000; 32(Suppl. 2): 2828.
  • 109
    Angelico M, Carli L, Piat C, Gentile S & Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997; 113(5): 16329.
  • 110
    Salerno F, Borroni G & Cazzaniga M, et al. Nadolol and isosorbide-5-mononitrate for preventing bleeding in cirrhotics with ascites [Abstract]. J Hepatol 1996; 25(Suppl. 1): 9292.
  • 111
    Merkel C, Marin R & Enzo E, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L’ipertensione portale. Lancet 1996; 348(9043): 167781.DOI: 10.1016/s0140-6736(96)05406-2
  • 112
    Merkel C, Marin R & Enzo E, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 31(2): 3249.
  • 113
    Spanish Variceal Bleeding Study Group. Propranolol + placebo vs. propranolol + isosorbide-5-mononitrate in the prevention of the first variceal bleeding. A multicenter double blind randomised controlled trial [Abstract]. J Hepatol 1999: 30(Suppl.): 5555.
  • 114
    Pietrosi G, D'Amico G, Pasta L & Patti R, et al. Isosorbide mononitrate (IMN) with nadolol compared to nadolol alone for prevention of first bleeding in cirrhosis. A double-blind placebo-controlled randomised trial [Abstract]. J Hepatol 1999; 30(Suppl.): 6666.
  • 115
    Pasta L, D'Amico G & Patti R, et al. Isosorbide mononitrate (IMN) with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis. A double-blind placebo-controlled randomized trial [Abstract]. J Hepatol 1999; 30 (Suppl.): 8181.
  • 116
    Avgerinos A, Armonis A & Manolakopoulos S, et al. Endoscopic sclerotherapy plus propranolol versus propranolol alone in the primary prevention of bleeding in high risk cirrhotic patients with esophageal varices: A prospective multicenter randomised trial. Gastrointest Endosc 2000; 51(6): 6528.
  • 117
    Laine L & Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med 1995; 123: 2807.
  • 118
    De BK, Ghoshal UC, Das T, Santra A & Biswas PK. Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomised controlled trial. J Gastroenterol Hepatol 1999; 14(3): 2204.
  • 119
    Sarin SK, Lamba GS, Kumar M, Misra A & Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340(13): 98893.
  • 120
    Lui HF, Stanley AJ & Forrest EH, et al. Primary prophylaxis of variceal haemorrhage: A randomised controlled trial comparing band ligation, propranolol andisosorbide mononitrate. Hepatology 1999; 30(4): 318A318A.
  • 121
    Burroughs AK, Jenkins WJ & Sherlock S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983; 309(25): 153942.
  • 122
    Lebrec D, Poynard T & Bernuau J, et al. A randomised controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984; 4(3): 3558.
  • 123
    Villeneuve JP, Pomier-Layrargues G & Infante-Rivard C, et al. Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial. Hepatology 1986; 6(6): 123943.
  • 124
    Cerbelaud P, Lavignolle A & Perrin D, et al. Propranolol et prevention des recidives de rupture de varice oesophagienne du cirrhotique. Gastroenterol Clin Biol 1986; 18: A10A10.
  • 125
    Queuniet AM, Czernichow P, Lerebours E, Ducrotte P, Tranvouez JL & Colin R. Controlled study of propranolol in the prevention of recurrent hemorrhage in cirrhotic patients. Gastroenterol Clin Biol 1987; 11(1): 417.
  • 126
    Gatta A, Merkel C & Sacerdoti D, et al. Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial. Digestion 1987; 37(1): 228.
  • 127
    Kobe E & Schentke KU. Unsichere rezidivprophylaxe von osophagusvarizenblutungen durch propranolol bei leberzirrhotikern: Eine prospective kontrollierte studie. Z Clin Med 1987; 42: 50710.
  • 128
    Colombo M, Franchis R, Tommasini M, Sangiovanni A & Dioguardi N. β-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomised controlled trial. Hepatology 1989; 9(3): 4338.
  • 129
    Colombo M, De Franchis R, Tommasini M, Sangiovanni A & Dioguardi N. β-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomised controlled trial. Hepatology 1989; 9(3): 4338.
  • 130
    Sheen IS, Chen TY & Liaw YF. Randomised controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. Liver 1989; 9(1): 15.
  • 131
    Garden OJ, Mills PR, Birnie GG, Murray GD & Carter DC. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. Gastroenterology 1990; 98(1): 18590.
  • 132
    Colman J, Jones P, Finch C & Dundley F. Propranolol in the prevention of variceal hemorrhage in alcoholic cirrhotic patients [Abstract]. Hepatology 1990; 12: 851851.
  • 133
    Rossi V, Cales P & Burtin P, et al. Prevention of recurrent variceal bleeding in alcoholicogy cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. Hepatology 1991; 12(3): 2839.
  • 134
    Bernard B, Lebrec D, Mathurin P, Opolon P & Poynard T. β-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis. Hepatology 1997; 25: 6370.
  • 135
    Gournay J, Masliah C, Martin T, Perrin D & Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000: 31: 123945.
  • 136
    Pasta L, D'Amico G & Patti R, et al. Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis. A double-blind placebocontrolled randomised trial [Abstract]. J Hepatol 1999; 30(Suppl.): 8181.
  • 137
    Masilah C, Gournay J, Martin T, Schneo M, Graf E & Perrin D. 5-Mononitrate d’isosorbide associè au propranolol contre propranolol seul aprè hémorragie par rupture de varices oesophagiennes: Un étude randomisée. Gastroenterol Clin Biol 1997; 21: A87A87.
  • 138
    Benedeto-Stojanov D, Tasiæ T, Bjelakoviæ G & Nagorni A. Prevention of recurrent upper gastrointestinal bleeding with propranolol in patients with cirrhosis undergoing endoscopic sclerotherapy [Abstract]. J Hepatol 2000; 32(Suppl. 2): 7272.
  • 139
    Bernard B, Lebrec D, Mathurin P, Opolon P & Poynard T. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol 1997; 26(2): 31224.
  • 140
    Villanueva C, Balanzo J & Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334(25): 16249.
  • 141
    Gallego A, Villanueva C & Ortiz J, et al. A randomised trial comparing endoscopic ligation with nadolol plus isosorbide 5-mononitrate for the prevention of variceal rebleeding. Preliminary results [Abstract]. J Hepatol 1998; 28(Suppl. 1): 7474.
  • 142
    Goulis J, Patch D, Greenslade L, Gerunda G, Merkel C & Burroughs AK. RCT of variceal ligation vs propranolol-isosorbide for variceal rebleeding with target pressure reduction: Methodological problems [Abstract]. J Hepatol 1998; 28(Suppl 1): 7474.
  • 143
    Minyana J, Gallego A & Vera JS, et al. Endoscopic ligation versus nadolol plus isosorbide-5-mononitrate for the prevention of variceal rebleeding. A prospective and randomised trial [Abstract]. Hepatology 1999; 30(4) 214A214A.
  • 144
    Escorsell A, Banares R & Gilabert R, et al. Transjugular intrahepatic portosystemic shunt vs. propranolol + isosorbide-mononitrate for the prevention of variceal rebleeding in patients with cirrhosis. Results of a randomised controlled trial [Abstract]. Hepatology 1998; 28: 770A770A.
  • 145
    Papatheodorisdis GV, Goulis J & Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 1999; 30: 61222.
  • 146
    Freedman AM & Sanyal AJ. Complications of transjugular intrahepatic portosystemic shunts. Semin Interventional Radiol 1994; 2(2): 16177.